Marc Mansour, (Immunovaccine CEO): “Older adults are a largely underserved population and have a significant unmet need for a strongly immunogenic platform like DepoVax™. This early data indicate a tolerable safety profile, which is a crucial milestone for an adjuvanting vaccine platform. We believe that these initial study results not only validate the platform in this population, they also open up potential opportunities for further collaborations and partnerships in the infectious disease field.”
Based on the vaccine candidate’s safety and immunogenicity demonstrated in the study, the independent Safety Review Committee (“SRC”) has allowed the study to proceed to its next step, which includes vaccinating patients with DPX-RSV at a higher dose.
Read more on: Immunovaccine
As this research may raise questions, we want to ask you to list the e-mail address that the VIB has made available for questions in your report or article. Everyone can contact us with questions about this research and other medical research: email@example.com.